Lung cancer is the leading cause of cancer mortality for men and women in United States. Key molecular changes, especially at early stages of carcinogenesis, represent potential pharmacological targets for lung cancer chemoprevention and therapy. Aberrant expression of cyclin E has been frequently observed in premalignant lung lesions, indicating that this is an early step in lung carcinogenesis. Overexpression of cyclin E also occurs in overt non-small cell lung cancers (NSCLCs) and has prognostic significance in NSCLCs.
Dartmouth researchers have now found that lung-specific overexpression of cyclin E in epithelial cells promotes anchorage-independent cell growth, lung hyperplasia, lung adenocarcinoma and local metastasis. Because lung adenocarcinoma is a prevalent characteristic of human lung cancer, a transgenic animal overexpressing cyclin E in lung epithelial cells now provides a clinically relevant model system of human lung carcinogenesis for the discovery and development of chemopreventive agents and therapeutic agents for the prevention and treatment of lung cancer, including premalignant lung lesions and overt non-small cell lung cancers.
This technology is claimed in the issued United States Patent No. 7,586,022. We are seeking an industrial partner interested in its commercialization. (Ref: J308)
Last Updated: 7/24/12